Search clinical trials for: Trastuzumab deruxtecan

Total 1194 results

Hoffmann-La Roche

Completed

Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen

Breast Cancer

India
Rita Sanghvi, Mehta

Completed

Neoadjuvant Biweekly Treatment Followed by Weekly Treatment of Breast Cancer

Breast Cancer

United States
Xijing Hospital

Unknown

Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer

Neoplasms, Breast

China
UNICANCER

Completed

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

Breast Cancer

France
Case Comprehensive Cancer Center
National Cancer Institute (NCI); United States Department of Defense

Completed

Chemotherapeutic Agents in Brain/Breast

Breast Cancer | Metastatic Cancer

United States
wang shusen

Recruiting

Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy (SMA-BC-002)

Breast Neoplasms

China
University of Chicago

Recruiting

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

Breast Cancer | HER2-positive Breast Cancer | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III

Nigeria
Genentech, Inc.

Active, not recruiting

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

Breast Cancer | Solid Tumor

United States, France, Spain, United Kingdom, Canada
Cephalon, Inc.

Completed

Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer

Breast Cancer

Austria, Belgium, France, Germany, Italy, Spain
Icahn School of Medicine at Mount Sinai

Terminated

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

Locally Advanced Breast Cancer

United States
Spanish Breast Cancer Research Group
GlaxoSmithKline

Completed

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Breast Cancer

Spain
Midwestern Regional Medical Center

Unknown

NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab for Women With Breast Cancer (NEOADAPT)

Breast Neoplasms

United States
Washington University School of Medicine
Novartis; Pfizer

Completed

Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer

Breast Neoplasms

United States
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

Breast Cancer

United States
Zagazig University

Active, not recruiting

Various Strategies to Reduce Acute Post Hemorrhoidectomy Pain: A Comparative Study

Acute Post Operative Pain

Egypt
M.D. Anderson Cancer Center

Completed

Bevacizumab in Multiple Phase I Combinations

Advanced Cancer

United States
Celgene

Terminated

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

Stage IV (Metastatic) Breast Cancer

United States
Hoffmann-La Roche

Completed

A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer

Breast Cancer

Turkey, Algeria, Morocco, Saudi Arabia, Tunisia
West German Study Group
Sanofi; Roche Pharma AG

Terminated

Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)

Breast Cancer

Germany
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Breast Cancer

Spain, China, United States, Italy, United Kingdom, Korea, Republic of, Belgium, France, Germany, Japan, Vietnam, Canada, Brazil, India, Malaysia, Taiwan, Australia, Austria, Thailand, Turkey, Hong Kong, Poland, Switzerland, Bulgaria, H... and more
Suzhou Zanrong Pharma Limited

Recruiting

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors

Advanced Solid Tumors | HER2-positive Breast Cancer

United States
Fudan University

Recruiting

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

HER2 Positive Early Breast Cancer

China
MedSIR

Active, not recruiting

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. (PHERGain)

Breast Cancer

Spain, Italy, France, United Kingdom, Germany, Portugal, Belgium
Japan Breast Cancer Research Group
Chugai Pharmaceutical

Unknown

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer (PRECIOUS)

HER2-positive Locally Advanced or Metastatic Breast Cancer

Japan
GlaxoSmithKline

Withdrawn

Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer (ELATE)

Neoplasms, Breast

Hungary, Norway, Austria, Spain
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Study for the Adjuvant Treatment of Breast Cancer

Breast Cancer

China
Baodong Qin

Recruiting

Efficacy and Safety of Precision Therapy in Refractory Tumor

Refractory Tumor | Rare Tumor

China
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Isolated Systolic Hypertension in the Elderly and Very Elderly

Isolated Systolic Hypertension

Germany
NSABP Foundation Inc
Genentech, Inc.; International Drug Development Institute

Completed

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

Breast Cancer

United States, Canada
Second Affiliated Hospital, School of Medicine,...

Recruiting

A Study for the Neoadjuvant Treatment of Breast Cancer

Breast Cancer

China
Merus N.V.

Completed

MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.

Breast Cancer Metastatic

United States, France, Belgium, Spain, United Kingdom, Netherlands, Portugal
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer

Breast Cancer

United States
Albert Einstein College of Medicine
Merck Sharp & Dohme LLC

Completed

Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy

Breast Cancer

United States
Institut Curie

Unknown

A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer (SHIVA)

Reccurent/Metastatic Solid Tumor Disease

France
National Cancer Institute (NCI)

Completed

Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic Osteosarcoma

Metastatic Osteosarcoma

United States
Spectrum Health - Lakeland

Terminated

Haloperidol, Droperidol, Ondansetron in Cannabis Hyperemesis

Cyclic Vomiting Syndrome

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Terminated

Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8

United States
University of Minnesota
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Active, not recruiting

Anti-inflammatory Therapy to Improve Outcomes After TPIAT

Pancreatitis, Chronic; Diabetes; Transplant

United States
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer

Inflammatory Breast Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Cardiac Toxicity

United States
Shanghai Pudong Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study (easy laugh)

Breast Cancer

China
Shi Yanxia

Recruiting

PERS Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer (PERS)

Breast Cancer | Effects of Chemotherapy | Breast Cancer Model

China
Yale University
Genentech, Inc.

Completed

Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer

Her2-Positive Breast Cancer

United States
National Cancer Institute (NCI)

Terminated

Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU

Breast Carcinoma | Stage IV Breast Cancer | Recurrent Breast Carcinoma

United States
Yizhuo Zhang

Recruiting

Ondansetron (ODF) Versus Ondansetron Intravenously for the Prevention of Chemotherapy-induced Nausea and Vomiting Compare in Children

Pediatric Solid Tumor, Unspecified, Protocol Specific

China
Tianjin Medical University General Hospital

Recruiting

Esketamine vs. Ketorolac for Prevention of Postoperative Pain and Cognitive Dysfunction After Total Knee Arthroplasty

Postoperative Pain | Postoperative Cognitive Dysfunction | Total Knee Arthroplasty

China
Jamia Millia Islamia

Recruiting

Intraligamentary Injections and Post-endodontic Pain

Pulpitis

India
Hoffmann-La Roche

Completed

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (BERENICE)

Breast Cancer

United States, Canada, Denmark, France, Italy, Poland, Portugal, Spain, United Kingdom, Norway, Germany, Mexico
University of Chicago

Withdrawn

Assessing the Response Rate of Neo-adjuvant Paclitaxel (Taxol) in Nigerian Women With Breast Cancer

Breast Cancer | Breast Cancer Stage II | Breast Cancer Stage III

Nigeria
Oslo University Hospital
The Research Council of Norway

Completed

N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy (MetAction)

Metastatic Cancer

Norway
Merck Sharp & Dohme LLC

Terminated

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Neoplasms

3

Subscribe